Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

European Innovation Council · Running

NAO.VNS NAO.VNS: A New Personalized Neural Stimulation Therapy For Drug-resistant Epilepsy

Coordinator
Synergia Medical, Belgium
Runs
1 March 2023 to 31 August 2025
Status
Running
EU funding
€2.5m
Total cost
€4.5m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190198268

What the project is doing

In the project's own words, from its summary on CORDIS.

19.5M world population suffer from Drug-Resistant Epilepsy (DRE) with symptoms poorly controlled. 8M are not eligible for brain surgery. Vagus nerve stimulation is nowadays the best treatment option. But unfortunately, current solutions do not reply to the clinical need. They cannot adapt to each patient making the patient's therapeutic journey complicated and expensive. We created NAO.VNS, the next-generation implantable vagus nerve neurostimulator.

We replaced metal wires by optical fibres to convert optical energy to electrical impulses rendering the device compliant with MRI & brain scans essential for disease diagnosis or treatment. Through NAO.VNS, patients & physicians receive remote feedback on the direct effect & efficacy of the neural stimulation, to precisely & uniquely adapt therapy. Through EIC funding, we will complete a clinical pilot trial & a pivotal study in the EU/US to initiate market approvals.

We expect to generate €89M by 2028 selling in the EU/US.

Topics

Who is involved

OrganisationCityCountryRole
Synergia MedicalMont-Saint-GuibertBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI